SCHEMBL40527

SCHEMBL40527

C[C](C)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.65
MAPT P10636 3/20 0.65
WDR5 P61964 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
ALDH1A1 P00352 3/20 0.50
MMP3 P08254 1/20 0.50
BCL2L1 Q07817 1/20 0.50
HPGD P15428 2/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
PDCD1 Q15116 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
PTPN1 P18031 1/20 0.46
GSK3B P49841 1/20 0.46
CDC25B P30305 1/20 0.45
ATM Q13315 1/20 0.45
FFAR1 O14842 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5712083 0.88 SMN1; SMN2 (0.48) SMN1; SMN2MAPTWDR5L3MBTL1BCL2L1
SCHEMBL10877617 0.82 CES2 (0.52) SMN1; SMN2MAPTL3MBTL1ALDH1A1HPGD
SCHEMBL6567 0.82
SCHEMBL28658039 0.79 CES2 (0.50) SMN1; SMN2MAPTL3MBTL1ALDH1A1HPGD
SCHEMBL23965711 0.79 SMN1; SMN2 (0.60) SMN1; SMN2MAPTWDR5L3MBTL1ALDH1A1
SCHEMBL4502407 0.79 SMN1; SMN2 (0.60) SMN1; SMN2MAPTWDR5L3MBTL1ALDH1A1
SCHEMBL3656317 0.79 SMN1; SMN2 (0.60) SMN1; SMN2MAPTWDR5L3MBTL1ALDH1A1
SCHEMBL7738989 0.79 MAPT (1.00) SMN1; SMN2MAPTL3MBTL1ALDH1A1HPGD
SCHEMBL51207 0.79 MAPT (1.00) SMN1; SMN2MAPTL3MBTL1ALDH1A1HPGD
SCHEMBL7252924 0.79 MAPT (1.00) SMN1; SMN2MAPTL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110945418-B Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element 日产化学株式会社 2022-04-26 CN claimed
CN-113728270-A Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same 日产化学株式会社 2021-11-30 CN claimed
CN-110945418-A Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element 日产化学株式会社 2020-03-31 CN claimed
EP-3068405-B1 PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES INC (US) 2019-05-01 EP claimed
EP-3323414-A1 INHIBITORS OF NEDD8-ACTIVATING ENZYME Millennium Pharmaceuticals, Inc. (US) 2018-05-23 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
US-5837873-A PROTECTED OXYDIAMINES ABBOTT LABORATORIES (US) 1998-11-17 US claimed
CN-113454526-B Liquid crystal aligning agent and liquid crystal display element using same 日产化学株式会社 2024-06-21 CN disclosed
CN-113330363-B Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element 日产化学株式会社 2024-06-07 CN disclosed
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof MELINTA SUBSIDIARY CORP. (US) 2024-06-04 US disclosed
CN-117986153-A Ionizable cationic lipid compound, and preparation method and application thereof 晟迪生物医药(苏州)有限公司 2024-05-07 CN disclosed
CN-114085243-B Pyrrolo [1,2-f ] [1,2,4] triazines useful for the treatment of respiratory syncytial virus infection 吉利德科学公司 2024-04-26 CN disclosed
WO-2024086717-A2 HETEROARYL ENHANCERS OF THE PARTICULATE GUANYLYL CYCLASE RECEPTOR A UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-04-25 WO disclosed
US-4138451-A Phosphono-isocyano-acetates CIBA-GEIGY CORPORATION (US) 1979-02-06 US disclosed
US-4101464-A Process for preparing foamed solids using two or more azo compounds PENNWALT CORPORATION (US) 1978-07-18 US disclosed
US-4075236-A FROM ACID CHLORIDE, A HYDROPEROXIDE AND AN ALKALI METAL HYDROXIDE PENNWALT CORPORATION (US) 1978-02-21 US disclosed
US-4045520-A Process for the manufacture of thioformamido-phosphono-acetates CIBA-GEIGY CORPORATION (US) 1977-08-30 US disclosed
US-4014874-A Process for the manufacture of 3-substituted thiomethyl-7-amino-2-cephem-4-carboxylic acid compound CIBA-GEIGY CORPORATION (US) 1977-03-29 US disclosed
US-3993609-A ACID SENSITIVE AZO PROMOTERS PENNWALT CORPORATION (US) 1976-11-23 US disclosed
US-3932465-A ANTIBIOTIC CIBA-GEIGY CORPORATION (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof ADH5, ADH1A, ADH7 SMN1; SMN2 4370/4885MAPT 4170/4885WDR5 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.